Evommune, Inc. develops clinical-stage biotechnology therapies targeting key drivers of chronic inflammatory diseases. News about EVMN centers on its pipeline, including EVO756, an oral small-molecule MRGPRX2 antagonist, and EVO301, a long-acting IL-18 binding protein fusion protein.
Company updates commonly cover clinical data, development plans and regulatory disclosures for chronic spontaneous urticaria, atopic dermatitis, ulcerative colitis and migraine prophylaxis. Recurring corporate news also includes quarterly financial results, capital-structure actions, business updates and public-company milestones following Evommune’s completed initial public offering.
Evommune (NYSE: EVMN) presented Phase 2a data showing EVO301 met its primary endpoint in adults with moderate-to-severe atopic dermatitis. The 70-patient trial assigned 48 patients to EVO301 and 22 to placebo. At Week 12, the least-squares mean reduction in EASI, an eczema severity score, was 55% versus 22% with placebo (p<0.01), eight weeks after the last dose. Statistically significant separation was observed at Weeks 4 and 8. At Week 12, 63% achieved at least a 50% EASI improvement versus 23% on placebo; 29% achieved at least a 75% improvement versus 9%.
Treatment-related adverse events occurred in 10.4% versus 13.6% on placebo, with no treatment-related serious or severe adverse events or adverse-event discontinuations. Exploratory biomarkers showed reductions across several inflammatory pathways. Evommune plans to begin a global, subcutaneous Phase 2b dose-ranging trial in mid-2027.
Evommune (EVMN) will present Phase 2a EVO301 data in atopic dermatitis at the EADV Congress on October 1, 2026.
The late-breaking oral presentation in Vienna will cover a trial in patients with moderate-to-severe disease. EVO301 is an injectable designed to neutralize IL-18 activity. The presentation is scheduled for 4:30–4:45 p.m. CEST in Hall A.
Evommune (EVMN) reported top-line results from a randomized, double-blind, placebo-controlled, dose-ranging Phase 2b trial of oral MRGPRX2 antagonist EVO756 in adults with moderate-to-severe atopic dermatitis (AD).
The 12-week study, which enrolled 121 adults with follow-up to Week 14, did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12, nor any secondary endpoints at any dose tested. Based on these data, Evommune does not plan to advance EVO756 in AD. EVO756 was generally well tolerated, with a safety profile described as consistent with prior studies, and development will continue in migraine prophylaxis.
Evommune highlighted EVO301, its IL-18BP fusion protein, as the lead AD program following positive Phase 2a proof-of-concept results, with a Phase 2b trial planned for mid-2027. The company also states that its balance sheet supports operations into 2029.
Evommune (NYSE:EVMN) reported second-quarter 2026 results and pipeline updates for its chronic inflammatory disease programs. The company held $288.0 million in cash, cash equivalents and investments as of June 30, 2026, and expects this to fund operations through 2028.
Evommune plans to report top-line Phase 2b data for EVO756 in atopic dermatitis (AD) in September 2026 from a 120-patient, 12-week dose-ranging trial. A global Phase 2b migraine prophylaxis study of EVO756, enrolling about 330 adults with ≥6 migraine days per month, began in July 2026 with top-line data expected in 2027. Following a Phase 2b chronic spontaneous urticaria study that did not meet its primary endpoint, development of EVO756 in CSU has been discontinued.
For EVO301, Evommune will present the full positive Phase 2a AD dataset at an upcoming medical conference and plans a placebo-controlled, dose-ranging Phase 2b AD trial starting mid-2027. In Q2 2026, revenue was zero, research and development expenses were $26.4 million, general and administrative expenses were $8.5 million, and net loss was $32.2 million.
Evommune (NYSE: EVMN) reported dosing the first patient in a global Phase 2b randomized, double-blind, placebo-controlled, dose-ranging trial of EVO756, a potent, highly selective oral MRGPRX2 antagonist, for prophylactic treatment of refractory migraine in adults experiencing ≥6 migraine days per month.
The study will enroll approximately 330 patients across two active dose arms and placebo, with once-daily dosing for 12 weeks at doses up to 100 mg. According to Evommune, EVO756 is designed to inhibit three neuropeptides (PACAP, VIP, Substance P) acting through MRGPRX2 in human trigeminal neurons and meningeal mast cells. The primary endpoint is mean change from baseline in monthly migraine days, with key secondary endpoints including ≥50% and ≥75% responder rates, changes in monthly headache days, and acute migraine medication use. Top-line data are expected in 2027.
Evommune (NYSE:EVMN) reported top-line results from a Phase 2b trial of oral MRGPRX2 antagonist EVO756 in moderate-to-severe chronic spontaneous urticaria (CSU). The 160-patient study did not meet its primary UAS7 endpoint at 12 weeks. Development in CSU will stop, while programs in atopic dermatitis, migraine prophylaxis and IL-18BP candidate EVO301 continue, supported by cash runway into 2028.
Evommune (NYSE: EVMN) reported first-quarter 2026 results and program updates. Cash, cash equivalents and investments were $307.0M as of March 31, 2026. Enrollment is complete for Phase 2b EVO756 trials in CSU (N=160) and AD (N=120) with top-line readouts expected June 2026 and Q3 2026.
The company plans a mid-2026 Phase 2b in migraine and a mid-2027 Phase 2b subcutaneous trial for EVO301 following positive Phase 2a POC data. Q1 revenue was $0; net loss was $21.7M.
Evommune (NYSE: EVMN) will host a KOL webinar on April 13, 2026 at 11:00 a.m. PT (2:00 p.m. ET) to discuss the migraine treatment landscape and MRGPRX2 inhibition.
The company highlighted expansion of EVO756 into migraine prophylaxis and said a Phase 2b study is planned to begin in 3Q26. Presenters include Stewart Tepper, M.D., and Greg Dussor, Ph.D. A live Q&A will follow and the webcast will be archived for 90 days.
Evommune (NYSE: EVMN) reported positive Phase 2a proof-of-concept results for EVO301 in atopic dermatitis, showing a 33% placebo-adjusted EASI improvement and 23% placebo-adjusted IGA 0/1 at week 12 after two doses. The company also expects EVO756 Phase 2b top-line readouts in CSU in 2Q26 and AD in 2H26. Evommune closed a $125 million private placement and reported $216.7 million cash, extending runway through 2028; FY2025 revenue rose to $13.0 million from $7.0 million in 2024.
Evommune (NYSE: EVMN) entered a securities purchase agreement to sell 4,494,279 shares of common stock at $27.88 per share for gross proceeds of approximately $125 million. The private placement is expected to close on or about February 17, 2026, subject to customary conditions.
Placement agents and an advisor assisted the deal. Evommune intends to use net proceeds to advance its clinical development programs and for general corporate purposes, and agreed to file a registration statement for resale of the issued shares.